Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 9—September 2012

Dispatch

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

Liesbet Van Heirstraeten, Samuel Coenen, Christine Lammens, Niel Hens, Herman Goossens, and Surbhi Malhotra-KumarComments to Author 
Author affiliations: University of Antwerp, Antwerp, Belgium (L. Van Heirstraeten, S. Coenen, C. Lammens, N. Hens, H. Goossens, S. Malhotra-Kumar); and University of Hasselt, Hasselt, Belgium (N. Hens)

Main Article

Table

Characteristics of macrolide-resistant Streptococcus pyogenes used in competition experiments and relative fitness* of the erm(A)-emm77 geno-emm-type against competitor strains, Belgium, 1999–2009

Geno-emm-type Macrolide MIC, mg/L
Relative fitness (SD)†
p value, t test
Erythromycin Clindamycin erm(A)-emm77 Competitor
erm(A)-emm77 2 0.125 ND ND ND
erm(B)-emm28 >512 >512 1.03 (0.09) 0.98 (0.09) 0.662
erm(B)-emm22 >512 >512 1.27 (0.15) 0.79 (0.09) 0.080
erm(B)-emm11 >512 256 2.12 (0.28) 0.48 (0.06) 0.013
mef(A)-emm12 8 0.125 1.29 (0.18) 0.78 (0.11) 0.105
mef(A)-emm4 8 <0.03 1.55 (0.15) 0.65 (0.06) 0.047
mef(A)-emm1 16 0.5 1.01 (0.05) 1.00 (0.06) 0.934

*The ability of the bacteria to survive and reproduce. ND, no data.
†Average of duplicate experiments.

Main Article

TOP